Information Provided By:
Fly News Breaks for January 31, 2020
Jan 31, 2020 | 08:16 EDT
Baird analyst Michael Ulz lowered his price target on Alexion to $140 from $165 following Q4 results which was in-line with its preannouncement. The analyst said its guidance was below expectations citing pricing headwinds in 2020 for its Ultomiris which continues to show strong conversion. Ulz said the company's Soliris neurology franchise remains its key near-term growth driver. Ulz maintained his Outperform rating on Alexion shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN